Core Viewpoint - The stock of Basestone Pharmaceuticals (02616) has seen an increase of over 4%, currently trading at 5.82 HKD, with a transaction volume of 24.98 million HKD, following the announcement of its drug being included in the national medical insurance list in China [1] Group 1 - Basestone Pharmaceuticals announced that its drug, Pulatinib (100 mg capsules), has been included in the latest version of the National Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List published by the National Healthcare Security Administration of China, which will take effect on January 1, 2026 [1] - Following this announcement, the stock price of Basestone Pharmaceuticals rose by 3.93% [1] Group 2 - On December 4, the non-executive director Hu Zhengguo increased his holdings in Basestone Pharmaceuticals by purchasing 1 million shares at a price of 5.7546 HKD per share, totaling 5.7546 million HKD [1] - After this purchase, Hu Zhengguo's total shareholding in the company increased to 3.471 million shares, representing a holding percentage of 0.24% [1]

Group 1 - The core point of the article is that 基石药业's drug, 普吉华 (普拉替尼胶囊, 100mg), has been included in the latest National Medical Insurance Drug List in China, which will take effect on January 1, 2026 [1] - Following the announcement, 基石药业's stock price increased by over 4%, with a current price of 5.82 HKD and a trading volume of 24.98 million HKD [1] - Additionally, non-executive director 胡正国 purchased 1 million shares of 基石药业 at a price of 5.7546 HKD per share, totaling 5.7546 million HKD, increasing his holdings to 3.471 million shares, representing 0.24% of the company [1]

Group 1 - The core viewpoint of the article is that 基石药业-B (02616) has seen a stock price increase of over 4%, currently trading at 5.82 HKD, with a transaction volume of 24.98 million HKD [1] - 基石药业's drug, 普吉华 (普拉替尼胶囊, 100 mg), has been included in the latest National Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List by China's National Healthcare Security Administration, which will take effect on January 1, 2026 [1] - On December 4, the non-executive director 胡正国 increased his holdings in 基石药业 by purchasing 1 million shares at a price of 5.7546 HKD per share, totaling 5.7546 million HKD, bringing his total holdings to 3.471 million shares, representing 0.24% of the company [1]

格隆汇12月10日丨根据联交所最新权益披露资料显示，2025年12月4日，基石药业-B(02616.HK)获非执行董事胡正国在场内以每股均价5.7546港元增持100万 股，涉资约575.46万港元。 | 表格序號 | 大股東/董事/最高行政人員名稱 作出披露的 買入 / 賣出或涉及的股 每股的平均價 | | | | 持有權益的股份數目 佔已發行的 有關事 | | | --- | --- | --- | --- | --- | --- | --- | | | 份數目 | 原因 | | | (請參閱上述 * 註解) 有投票權股 (日 / F | | | | | | | | 份百分比 | | | | | | | | ( % ) | | | DA20251205E00354 | 胡正國 | 1101(L) | 1,000,000(L | HKD 5.7546 | 3.471,000(L | 0.24(L)04/12/ | 增持后，胡正国最新持股数目为347.1万股，持股比例由0.17%上升至0.24%。 | 股份代號: | 02616 | | --- | --- | | 上市法國名稱: | 基石藥業 - B | | ...

（文章来源：每日经济新闻） 每经AI快讯，基石药业-B(02616.HK)早盘一度涨超3%，截至发稿，涨2.51%，报5.71港元，成交额 729.04万港元。 ...

责任编辑：卢昱君 基石药业-B（02616）盘中涨超3%，截至发稿，股价上涨1.97%，现报5.68港元，成交额1204.53万港 元。 12月8日，基石药业-B发布公告，公司普吉华®（普拉替尼胶囊，100 mg）已被纳入中国国家医疗保障 局公布的最新版《国家基本医疗保险、生育保险和工伤保险药品目录》，该目录将于2026年1月1日起正 式实施。 据介绍，普吉华®由基石药业合作伙伴Blueprint Medicines公司（已于2025年7月被赛诺菲收购）开发。 基石药业拥有普吉华®在大中华地区（包括中国内地、中国香港、中国澳门和中国台湾省地区）的独家 开发和商业化权利。2023年11月，基石药业将普吉华®在中国内地的独家商业化推广权授予上海艾力斯 医药科技股份有限公司。 基石药业-B（02616）盘中涨超3%，截至发稿，股价上涨1.97%，现报5.68港元，成交额1204.53万港 元。 12月8日，基石药业-B发布公告，公司普吉华®（普拉替尼胶囊，100 mg）已被纳入中国国家医疗保障 局公布的最新版《国家基本医疗保险、生育保险和工伤保险药品目录》，该目录将于2026年1月1日起正 式实施。 据介绍，普吉华 ...

Core Viewpoint - The announcement of the inclusion of the drug Pujihua (Pralsetinib capsules, 100mg) in China's National Medical Insurance Catalog has positively impacted the stock price of the company, leading to an increase of over 3% in early trading [1] Group 1: Stock Performance - The stock of the company, 基石药业-B, rose by over 3% in early trading and is currently up by 2.51%, priced at 5.71 HKD with a trading volume of 7.29 million HKD [1] Group 2: Drug Development and Commercialization - Pujihua has been developed by Blueprint Medicines, which was acquired by Sanofi in July 2025 [1] - The company holds exclusive development and commercialization rights for Pujihua in Greater China, including mainland China, Hong Kong, Macau, and Taiwan [1] - In November 2023, the company granted exclusive commercialization rights for Pujihua in mainland China to Shanghai Elios Pharmaceutical Technology Co., Ltd [1] Group 3: Regulatory Approval - The National Medical Insurance Catalog, which includes Pujihua, will officially take effect on January 1, 2026 [1]

Core Viewpoint - 基石药业-B's stock price increased by over 3% in early trading, reflecting positive market sentiment following the announcement of its drug being included in the national medical insurance list [1] Group 1: Company Announcement - 基石药业-B announced that its drug, 普吉华® (Pralsetinib capsules, 100 mg), has been included in the latest version of the National Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List by China's National Healthcare Security Administration [1] - The new drug list will officially take effect on January 1, 2026 [1] - 基石药业 holds exclusive development and commercialization rights for 普吉华® in Greater China, which includes mainland China, Hong Kong, Macau, and Taiwan [1] Group 2: Partnership and Commercialization - 普吉华® was developed by Blueprint Medicines, which is set to be acquired by Sanofi in July 2025 [1] - In November 2023, 基石药业 granted exclusive commercialization rights for 普吉华® in mainland China to Shanghai Elios Pharmaceutical Technology Co., Ltd [1]

Major Events - GuoXia Technology (02655) plans to conduct an IPO from December 8 to December 11, offering 33.85 million H-shares and introducing cornerstone investors such as Huikai Hong Kong [1] - Basilea Pharmaceutica AG (02616) has its drug Pujihua® (Pralsetinib Capsules) included in the National Medical Insurance Directory for 2025 [1] - Four Seasons Pharmaceutical (00460) sees its innovative drug XuanYueNing® included in the National Basic Medical Insurance Drug List for the first time [1] - Shanghai Pharmaceuticals (02607) successfully negotiates and includes Amisulpride Orally Disintegrating Tablets in the National Medical Insurance Directory [1] - Hansoh Pharmaceutical (03692) has its innovative drug Amelotex® approved for two new indications in the updated 2025 National Medical Insurance Directory [1] - Xiansheng Pharmaceutical (02096) sees EnzeShu® and EnDu® included in the updated National Medical Insurance Drug List [1] - Hutchison China MediTech (00013) has its drug Tazverik® included in the first edition of the National Commercial Health Insurance Innovative Drug List [1] - XuanZhu Biotechnology (02575) has its innovative drug XuanYueNing® included in the National Basic Medical Insurance Drug List for the first time [1] - Yino Pharmaceutical (02591) has its H-shares included in the list of eligible securities for the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect [1] - China Metallurgical Group (01618) and its subsidiaries plan to sell non-core business assets for approximately 60.68 billion yuan, focusing on core businesses in metallurgical engineering, non-ferrous metals, and mining engineering [1] - Cambridge Technology (06166) intends to invest a total of 405 million yuan to acquire and subscribe for shares in the Yangzhong Happiness Home Venture Capital Partnership Fund [1] Operating Performance - Dongfeng Motor Group (00489) reports cumulative automobile sales of 1.697 million units in the first 11 months, a year-on-year decrease of approximately 0.3% [2] - New天绿色能源 (00956) achieves a cumulative power generation of 1,336.89 million MWh in the first 11 months, an increase of 8.04% year-on-year [2] - Longyuan Power (00916) reports a cumulative power generation of approximately 6,909.64 million MWh in the first 11 months, a year-on-year growth of 0.41% [2] - Baolong Real Estate (01238) records a total contract sales of approximately 6.666 billion yuan in the first 11 months, a year-on-year decline of 43.2% [2]

（原标题：非执行董事胡正国增持基石药业(02616)100万股 每股作价约5.75港元） 智通财经APP获悉，香港联交所最新资料显示，12月4日，非执行董事胡正国增持基石药业(02616)100万 股，每股作价5.7546港元，总金额为575.46万港元。增持后最新持股数目为347.1万股，持股比例为 0.24%。 ...